# Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

> **NCT03451162** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** DHES0815A

## Key facts

- **NCT ID:** NCT03451162
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2021-07-16
- **Final completion:** 2021-07-16
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451162, "Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03451162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*